(MT Newswires) -- Pfizer Inc. (PFE) is purchasing cancer-drug maker Seagen Inc. (SGEN) for an enterprise value of $43 billion, using the biggest deal of the year to set its course out of the pandemic and back into mainstream pharma. Pfizer CEO Dr. Albert Bourla speaks to David Westin.
Market Closed -
Other stock markets
|
After market 06:30:10 pm | |||
28.38 USD | -0.21% | 28.38 | -0.02% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.42% | 161B | |
+31.06% | 682B | |
+30.35% | 586B | |
-3.42% | 364B | |
+18.02% | 327B | |
+4.27% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+8.12% | 165B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- INTERVIEW - Pfizer CEO Albert Bourla on the Seagen deal, growth and regulatory risks